AbbVie’s Q3 2026 Skyrizi net revenues face scrutiny ahead of the October 30 earnings release, with the Zacks consensus estimate at $5.71 billion, reflecting roughly 21% year-over-year growth from the $4.71 billion reported in Q3 2025. The immunology franchise continues to benefit from strong demand across psoriasis, psoriatic arthritis, and Crohn’s indications, supported by recent Phase 3 AFFIRM data showing superior clinical and endoscopic outcomes versus placebo in Crohn’s disease and positive long-term IBD results presented at UEGW 2026. These developments reinforce Skyrizi’s competitive positioning against IL-23 and JAK inhibitors, while sequential momentum from Q2’s $5.51 billion print and ongoing market-share gains provide a solid base. Any deviation from consensus will hinge on prescription trends, competitive pressures in IBD, and potential label updates.